Utilization of adipocyte-derived lipids and enhanced intracellular trafficking of fatty acids contribute to breast cancer progression

Table 1 Immunohistochemistry staining intensity of FABP5 in various breast cancer patients

Clinicopathological features	Expression (N = 60)		p value
Clinicopathological features	- ~Medium n (%)	High n (%)	p value
Age, years			0.166
≤ 50	25 (49.0)	2 (22.2)
> 50	26 (51.0)	7 (77.8)
BMI ^a (Kg/m²)			1.000
18.5–24.9	33 (78.6)	6 (75.0)
≥ 25	9 (21.4)	2 (25.0)
Tumor size			0.712
≤ 2 cm	18 (35.3)	4 (44.4)
> 2 cm	33 (64.7)	5 (55.6)
Grade			0.036
I-II	41 (80.4)	4 (44.4)
III	10 (19.6)	5 (55.6)
Lymph node metastasis			1.000
Negative	28 (54.9)	5 (55.6)
Positive	23 (45.1)	4 (44.4)
Estrogen receptor			0.032
Negative	19 (37.3)	7 (77.8)
Positive	32 (62.7)	2 (22.2)
Progesterone receptor			0.281
Negative	28 (54.9)	7 (77.8)
Positive	23 (45.1)	2 (22.2)
Ki67			0.704
Low	18 (35.3)	2 (22.2)
High	33 (64.7)	7 (77.8)
P53			1.000
Negative	19 (37.3)	3 (33.3)
Positive	32 (62.7)	6 (66.7)
HER2^b			0.225
Negative	23 (57.5)	6 (85.7)
Positive	17 (42.5)	1 (14.3)
Subtypes^b			0.001
TNBC	6 (15.0)	6 (85.7)
Non-TNBC	34 (85.0)	1 (14.3)

^aInformation on some patients was not well documented.^bHER2 status was detected using Fluorescence in Situ Hybridization (FISH) and patients with unknown HER2 status were not included in the statistical analysis

ISSN: 1478-811X